RxDoctor Payments Data

Marcella Miller

Acute Care · Arlington, TXNPI 1962950113

Payments from drug & device makers

$3,341in general payments, 2019–2025

Across 149 payments — averaging $22.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$725
  • Abiomed$464
  • AstraZeneca$434
  • Insmed, Inc.$314
  • Boehringer Ingelheim$261
  • AbbVie$199
  • plus $944 from 18 others

What the payments were for

  • Food & beverage$3,341100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,341 in reported general payments places this provider in the 90th percentile of 2,323 acute care providers in Texas.

See all acute care providers in Texas

Medicare billing

Part B allowed, 2024
$15,534
Medicare patients
117
Services billed
219

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter88$87,022
Breztri AerosphereBudesonide/Glycopyr/Formoterol40$29,046
Breo ElliptaFluticasone/Vilanterol26$15,559
Stiolto RespimatTiotropium Br/Olodaterol Hcl21$12,701
Spiriva RespimatTiotropium Bromide15$10,378
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$10,378
XareltoRivaroxaban15$8,447
SymbicortBudesonide/Formoterol Fumarate19$5,181
Albuterol Sulfate HfaAlbuterol Sulfate71$1,620
Azelastine Hcl20$594
Montelukast Sodium73$513
Prednisone14$77

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$725$112,960126 claims
AstraZenecaBreztri Aerosphere, Symbicort$434$34,22859 claims
Boehringer IngelheimStiolto Respimat, Spiriva Respimat$261$23,07936 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,323 acute care providers in Texas.

Other acute care in Arlington

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →